MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Pentosan Polysulfate Sodium Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Pentosan Polysulfate Sodium (PPS; Elmiron, Cartrophen, SP-54) is a semi-synthetic, heparin-like glycosaminoglycan made from beechwood xylan, averaging roughly 4,000-6,000 daltons. Orally, it is FDA-approved for interstitial cystitis and is thought to repair the protective glycosaminoglycan layer of the bladder lining (PMID 16706553). In joints it acts as a candidate disease-modifying osteoarthritis drug, boosting proteoglycan and hyaluronan synthesis while inhibiting cartilage-degrading enzymes, which is why a subcutaneous ~2 mg/kg weekly protocol has been studied for knee osteoarthritis (PMC2873929) and is now in Phase 3 (NCT04809376). The clinically approved dose is 100 mg orally three times daily (300 mg/day); the subcutaneous figures here are an educational reconstitution reference for the investigational joint regimen, not a licensed route. Long-term high cumulative exposure carries a documented risk of pigmentary maculopathy (PMID 29801663).
Reconstitute: Add 1 mL bacteriostatic water → 100 mg/mL concentration.
Typical dose: 300 mg/day oral (100 mg 3×/day, FDA-approved); ~2 mg/kg SC weekly (investigational, off-label joint use)
Easy measuring: At 100 mg/mL, 1 unit = 0.01 mL = 1 mg (1000 mcg) on a U-100 insulin syringe.
Storage: Lyophilized PPS powder stored frozen at −20 °C; once reconstituted, refrigerate at 2-8 °C and use within roughly 4 weeks. Commercial Elmiron capsules are stored at controlled room temperature, protected from light and moisture.
Half-life: About 20-27 h for total plasma radioactivity after oral dosing; the intact drug clears far faster (IV half-life ~13-45 min, dose-dependent due to saturable hepatic/splenic uptake).
Route: Oral (FDA-approved: 100 mg capsules 3×/day for interstitial cystitis). Subcutaneous injection (~2 mg/kg weekly) is investigational for osteoarthritis; the SC model here is educational only.
Status: FDA-approved 1996 as oral Elmiron for interstitial cystitis. SC injectable for OA is investigational (Phase 3, FDA Fast Track) and not approved; veterinary PPS (Cartrophen, Zycosan) is approved for animals.
About Pentosan Polysulfate Sodium
Pentosan Polysulfate Sodium (PPS) is a semi-synthetic, sulfated polysaccharide (a heparin-like glycosaminoglycan) derived from beechwood xylan. It is the only oral medicine FDA-approved (since 1996) to relieve the bladder pain and discomfort of interstitial cystitis, marketed as Elmiron, and is taken clinically by mouth as a 100 mg capsule three times daily (300 mg/day) on an empty stomach [1]. A separate injectable, subcutaneous use for osteoarthritis and joint health is investigational and not FDA-approved; the SC figures below are an educational reconstitution and measurement reference, not the licensed oral route.\n\nThe most-studied injectable Pentosan Polysulfate Sodium dosage for joints is about 2 mg/kg given subcutaneously once weekly, the regimen used in the Kumagai (2010) open knee-osteoarthritis trial and echoed in animal and Phase 3 work [4][6]. Trials typically begin with two small sensitivity test injections (25 mg, then 50 mg) before the weekly maintenance dose. This guide models a 100 mg vial reconstituted with 1.0 mL of bacteriostatic water (100 mg/mL), so each insulin-syringe unit equals 1 mg (1000 mcg): a 25 mg test dose ≈ 25 units, 50 mg ≈ 50 units, and a 100 mg maintenance dose ≈ 100 units (1.0 mL). Heavier adults dosed at a true 2 mg/kg (roughly 120-160 mg) split the dose across two injections [4].\n\nFrequency: Inject once weekly subcutaneously for the modeled osteoarthritis protocol (the FDA-approved interstitial-cystitis product is instead taken orally three times daily). PPS is presented here for educational purposes only and is not medical advice.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 1.0 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly down the inner wall of the 100 mg PPS vial; do not aim the stream directly at the powder and avoid vigorous shaking, because this sulfated polysaccharide foams readily.
Gently swirl or roll the vial until the powder is fully dissolved into a clear solution; the result is 100 mg/mL, so 1 insulin-syringe unit equals 1 mg (1000 mcg).
Store refrigerated at 2-8 °C; draw the prescribed number of units (25 mg test ≈ 25 units / 0.25 mL, 50 mg test ≈ 50 units / 0.50 mL, 100 mg maintenance ≈ 100 units / 1.0 mL).
Educational note: the FDA-approved PPS product is taken ORALLY (100 mg capsules three times daily) for interstitial cystitis; these subcutaneous figures model the investigational ~2 mg/kg weekly osteoarthritis protocol. Inject slowly into subcutaneous tissue, expect occasional injection-site bruising given PPS's heparin-like activity, and rotate sites.
Interactive Pentosan Polysulfate Sodium Syringe Calculator
Currently visualizing the 100 mg vial reconstituted with 1 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 100mg dry powder in 1mL water yields 100.00 mg/mL. To evaluate a 250mcg dose, pull to 0.3 units (0 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Sensitivity test injection 1 (week 0) | 25000 mcg (25 mg) | 25 units (0.25 mL) |
| Sensitivity test injection 2 (a few days later) | 50000 mcg (50 mg) | 50 units (0.50 mL) |
| Weekly maintenance ≈ 2 mg/kg (weeks 1-6) | 100000 mcg (100 mg) | 100 units (1.00 mL) |
Administration guidelines: Refer to guidelines | 1 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 100 mg vial.
Peptide Vials (Pentosan Polysulfate Sodium, 100 mg each):
- check8-week weekly course at 100 mg/dose ≈ 8 vials (800 mg), plus ~1 vial for the two sensitivity test doses (25 mg + 50 mg)
- check12 weeks ≈ 12-13 vials (1,200-1,300 mg)
- check16 weeks ≈ 16-17 vials (1,600-1,700 mg); heavier adults at a true 2 mg/kg (120-160 mg) need roughly 1.5 vials per week
Insulin Syringes (U-100):
- checkOnce-weekly dosing: about 1 syringe per week when the dose fits one 1 mL syringe (100 mg ≈ 100 units)
- check8 weeks ≈ 8-10 syringes (includes the 2 test-dose injections); 12 weeks ≈ 12-14; 16 weeks ≈ 16-18
- checkDoses above 100 mg (2 mg/kg in heavier adults) exceed one syringe and are split into two injections
Bacteriostatic Water (30 mL bottles): Use 1 mL per 100 mg vial for reconstitution.
- check8 weeks ≈ 9 mL ≈ 1 bottle
- check12 weeks ≈ 13 mL ≈ 1 bottle
- check16 weeks ≈ 17 mL ≈ 1 bottle
Alcohol Swabs:
- check1-2 swabs per dose (vial top + injection site)
- check8 weeks ≈ 20-40 swabs; 12 weeks ≈ 30-55 swabs
- check16 weeks ≈ 40-70 swabs; keep extras for re-swabbing multi-dose vials
Mechanism of Action (MOA)
Pentosan Polysulfate Sodium is a semi-synthetic, negatively charged glycosaminoglycan produced by extracting xylan (a pentose polysaccharide) from beechwood hemicellulose and esterifying its hydroxyl groups with sulfate. The finished drug is a polydisperse mixture with an average molecular weight of roughly 4,000-6,000 daltons, structurally and functionally heparin-like, which underlies both its therapeutic actions and its anticoagulant side effects [1][8].\n\nIn the bladder, the leading hypothesis for interstitial cystitis is a defective glycosaminoglycan mucus layer that normally shields the urothelium from irritating urinary solutes such as potassium. PPS is thought to adhere to and replenish or repair this protective GAG coating, restoring the permeability barrier and reducing the inflammatory and pain signaling that follow urothelial exposure; an in-vitro anti-inflammatory effect has also been described [1][3]. Because the mechanism is reparative rather than analgesic, oral PPS works slowly, with meaningful relief often taking weeks to months [3].\n\nIn cartilage and joints, PPS behaves as a candidate disease-modifying osteoarthritis drug (DMOAD). It stimulates chondrocytes and synoviocytes to synthesize proteoglycans and hyaluronan, inhibits cartilage-degrading enzymes (matrix metalloproteinases, aggrecanases, and elastase), dampens pro-inflammatory mediators, and exerts a fibrinolytic, antithrombotic action that is believed to clear microthrombi in subchondral bone and improve blood flow to the joint [2][4]. These mechanisms are why injectable PPS is being investigated subcutaneously for knee osteoarthritis [4][6].\n\nPharmacokinetics are unusual and route-dependent. Oral bioavailability is very low: only about 6% of a radiolabeled oral dose reaches the systemic circulation, and under 1% as intact parent compound, with roughly 84% excreted unchanged in the feces; the plasma half-life of total radioactivity is approximately 20-27 hours for 300-450 mg oral doses [1]. The intact drug itself, given intravenously, clears far faster, with a half-life of about 13-45 minutes that lengthens with dose because hepatic and splenic uptake is saturable; plasma clearance is roughly 50 mL/min and only about 8% of an IV dose appears in urine, indicating extensive metabolism rather than renal elimination [8]. Subcutaneous delivery achieves substantially higher systemic exposure than oral dosing and, in mucopolysaccharidosis VI rats, weekly SC injection matched or outperformed daily oral PPS with better tissue distribution [5].\n\nThe real-world, FDA-approved route is oral; the subcutaneous reconstitution scheme on this page is an educational measurement convention used across this site to model the investigational ~2 mg/kg weekly joint protocol, not a licensed delivery method [4][6].
Clinical Trial Efficacy Highlights
- starAnderson and Perry (2006, Drugs) reviewed pentosan polysulfate for interstitial cystitis and concluded that oral PPS at 300 mg/day (100 mg three times daily) produces modest but statistically significant relief of bladder pain versus placebo, with a slow onset of action that often requires weeks to months of continuous use, consistent with a glycosaminoglycan-repair rather than analgesic mechanism [3].
- starKumagai and colleagues (2010, BMC Clinical Pharmacology) treated 20 patients (Kellgren-Lawrence grade 1-3 knee osteoarthritis) with subcutaneous PPS at 2 mg/kg weekly for 6 weeks after two test injections (25 mg then 50 mg); knee flexion angle improved from 132.2° to about 142.9° at week 8, VAS pain on a 50 m walk fell from 27.7 to 8.7 by week 52, and the cartilage-degradation biomarker C2C dropped from 39.7 to 31.4 ng/mL, with effusions resolving quickly [4].
- starFrohbergh and colleagues (2014, PLoS ONE) showed in mucopolysaccharidosis VI rats that once-weekly subcutaneous PPS (1, 2, or 4 mg/kg human-equivalent for 6 months) produced equal or better therapeutic effects than daily oral dosing, with optimal results at 2 mg/kg and greater tissue distribution after SC versus oral administration, supporting the rationale for injectable joint protocols [5].
- starThe FDA Elmiron prescribing information documents that after oral dosing only about 6% of a radiolabeled dose is systemically absorbed (under 1% as intact drug), roughly 84% is excreted unchanged in feces, and the plasma half-life of total radioactivity is about 20-27 hours, explaining why the oral product is dosed three times daily yet acts slowly [1].
- starIARC mechanistic data report that the intact drug given intravenously has a short, dose-dependent half-life of about 13-45 minutes (lengthening at higher doses due to saturable hepatic and splenic metabolism), a plasma clearance near 50 mL/min, and only about 8% urinary recovery, indicating predominantly metabolic rather than renal clearance [8].
- starParadigm Biopharmaceuticals' Phase 3 program (NCT04809376) is evaluating subcutaneous PPS versus placebo for knee osteoarthritis pain, with Stage 1 randomizing roughly 468 participants across three PPS dose regimens and placebo over 6 weeks (twice-weekly visits); the injectable program has received FDA Fast Track designation, though final results were not yet published [6].
- starPearce, Chen and Jain (2018, Ophthalmology) described a distinctive pigmentary maculopathy in a retrospective case series of six patients with long-term, high-cumulative PPS exposure, establishing the now well-recognized risk of irreversible retinal toxicity that prompted updated FDA labeling and routine ophthalmologic monitoring [7].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningGastrointestinal effects are the most common with oral PPS, including diarrhea, nausea, heartburn, and abdominal pain; these are usually mild and dose-related [1].
- warningHeparin-like anticoagulant activity creates a real bleeding risk: rectal hemorrhage was reported in about 6.3% of treated patients, along with bruising, epistaxis, and gum bleeding, and with subcutaneous injection some patients develop injection-site bruising or bleeding [1][4].
- warningPigmentary maculopathy is the most serious documented risk: dose- and duration-dependent retinal toxicity that can cause difficulty reading, slow adaptation to dim light, and blurred vision, may be irreversible, and can progress even after the drug is stopped; baseline and periodic eye examinations are recommended [7][1].
- warningAlopecia can occur, usually as reversible hair loss (often an alopecia-areata pattern) beginning within the first weeks of treatment [1].
- warningMild liver enzyme elevation (transaminase increase in roughly 1.2% of patients) has been reported; caution is advised in hepatic impairment [1].
- warningSubcutaneous administration specifically can cause injection-site pain (occasionally severe but transient) and small subcutaneous bleeds, as seen in the knee-osteoarthritis trial [4].
- warningPPS is contraindicated in known hypersensitivity to the drug or structurally related compounds; because of its anticoagulant action, combining it with heparin, warfarin, high-dose aspirin, or NSAIDs can raise bleeding risk, and it is generally held before surgery [1].
- warningRegulatory and research status: only the oral product is FDA-approved (interstitial cystitis); subcutaneous use for osteoarthritis is investigational and not FDA-approved, so the injection figures here are educational only and not a substitute for medical care.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Pentosan Polysulfate Sodium dosage?expand_more
The FDA-approved, clinically standard Pentosan Polysulfate Sodium dosage is 100 mg by mouth three times daily (300 mg/day) for interstitial cystitis, taken on an empty stomach. A separate investigational subcutaneous protocol for joint and cartilage health uses about 2 mg/kg once weekly, usually preceded by two small sensitivity test injections (25 mg, then 50 mg), as in the Kumagai 2010 knee-osteoarthritis trial. The injectable joint use is off-label and not FDA-approved; the subcutaneous figures on this page are an educational reconstitution reference, not medical advice.
Is Pentosan Polysulfate Sodium FDA approved?expand_more
Yes, but only in one form. Oral pentosan polysulfate sodium (Elmiron) was FDA-approved in 1996 and remains the only oral drug approved to relieve the bladder pain of interstitial cystitis. The subcutaneous injectable used for osteoarthritis is investigational (Paradigm Biopharmaceuticals, Phase 3, with FDA Fast Track designation) and is not approved. Veterinary PPS products such as Cartrophen and Zycosan are separately approved for animal osteoarthritis. The injection figures here are educational only.
How do you reconstitute Pentosan Polysulfate Sodium for a subcutaneous protocol?expand_more
For the educational model on this page, draw 1.0 mL of bacteriostatic water and add it slowly down the inner wall of a 100 mg vial, avoiding vigorous shaking because the sulfated polysaccharide foams easily. Swirl gently until clear. This yields 100 mg/mL, so each insulin-syringe unit equals 1 mg (1000 mcg): a 25 mg test dose is about 25 units, 50 mg is 50 units, and a 100 mg maintenance dose is 100 units (1.0 mL). Store refrigerated at 2-8 °C and use within about 4 weeks. Remember the FDA-approved product is actually taken orally.
What is the half life of Pentosan Polysulfate Sodium?expand_more
It depends on route and on what is measured. After oral dosing, the plasma half-life of total radioactivity is roughly 20-27 hours, but oral bioavailability is very low (about 6% of a radiolabeled dose, under 1% as intact drug), and around 84% is excreted unchanged in feces. The intact drug given intravenously clears much faster, with a half-life of about 13-45 minutes that lengthens with higher doses because hepatic and splenic metabolism is saturable.
What are the most important Pentosan Polysulfate Sodium side effects?expand_more
Common oral effects are gastrointestinal (diarrhea, nausea, heartburn) and reversible hair loss. Because PPS is heparin-like, it raises bleeding risk (rectal hemorrhage in about 6.3% of patients, bruising, and injection-site bleeding with subcutaneous use). The most serious risk is pigmentary maculopathy, a dose- and duration-dependent retinal toxicity that can cause vision changes, may be irreversible, and can progress after stopping; baseline and periodic eye exams are advised. Avoid combining with other anticoagulants or high-dose NSAIDs without medical supervision.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Pentosan Polysulfate Sodium, plus the universal dosing calculator.
Academic References & Study Citations
ELMIRON (pentosan polysulfate sodium) 100 mg Capsules — FDA Prescribing Information (clinical pharmacology, dosage, warnings including maculopathy). U.S. Food and Drug Administration. View Scientific Paper →
Pentosan Polysulfate Sodium — Monograph for Professionals (indications, mechanism, pharmacokinetics, warnings). Drugs.com / AHFS. View Scientific Paper →
Anderson VR, Perry CM. Pentosan polysulfate: a review of its use in the relief of bladder pain or discomfort in interstitial cystitis. Drugs. 2006;66(6):821-835. View Scientific Paper →
Kumagai K, Shirabe S, Miyata N, et al. Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis — an open clinical trial. BMC Clin Pharmacol. 2010;10:7. View Scientific Paper →
Frohbergh M, Ge Y, Meng F, et al. Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment. PLoS ONE. 2014;9(6):e100882. View Scientific Paper →
Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain (PARA_OA_002), Phase 3. ClinicalTrials.gov Identifier NCT04809376. View Scientific Paper →
Pearce WA, Chen R, Jain N. Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium. Ophthalmology. 2018;125(11):1793-1802. View Scientific Paper →
Pentosan Polysulfate Sodium — Mechanistic and Other Relevant Data (pharmacokinetics, metabolism, distribution). IARC Monographs, NCBI Bookshelf NBK350418. View Scientific Paper →